Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

被引：0
|
作者：
Lorusso, D. [1 ,2 ]
Xiang, Y. [3 ]
Hasegawa, K. [4 ]
Scambia, G. [2 ,5 ]
Leiva Galvez, M. H. [6 ]
Elias, P. Ramos [7 ]
Acevedo, A. [8 ]
Bednarikova, M. [9 ,10 ]
Gomes, A. J. P. D. S. [11 ]
Mejia, F. Contreras [12 ]
Reiss, A. [13 ]
Zagouri, F. [14 ]
Lee, J-Y. [15 ]
Saevets, V. [16 ]
Ayhan, A. [17 ]
Liu, P. [18 ]
Yamada, K. U. [18 ]
Puglisi, M. [18 ]
Pignata, S. [19 ]
Duska, L. [20 ]
机构：
[1] Fdn Policlin Univ A Gemelli IRCCS, Gynaecol Oncol Unit, Rome, Italy
[2] Univ Cattolica Sacro Cuore, Rome, Italy
[3] Peking Union Med Coll Hosp, Natl Clin Res Ctr Obstetr & Gynecol Dis, Dept Obstet & Gynecol, Beijing, Peoples R China
[4] Saitama Med Univ, Gynecol Oncol Dept, Int Med Ctr, Saitama, Japan
[5] Fdn Policlin Univ A Gemelli IRCCS, Sci Directorate, Rome, Italy
[6] Inst Oncol & Radioterapia Clin Ricardo Palma, Med Oncol, Lima, Peru
[7] Edificio Integra Med Ctr, Integra Canc Inst, Guatemala City, Guatemala
[8] Oncocentro, Med Oncol, Vina Del Mar, Chile
[9] Univ Hosp Brno, Brno, Czech Republic
[10] Masaryk Univ, Fac Med, Brno, Czech Republic
[11] Liga Norte Riograndense Contra O Canc, Med Oncol & Med Oncol Res, Natal, Brazil
[12] Inst Nacl Cancerol, Clin Oncol, Bogota, Colombia
[13] Rambam Med Ctr, Gynecooncol Unit, Haifa, Israel
[14] Alexandra Gen Hosp, Clin Therapeut, Athens, Greece
[15] Yonsei Univ, Severance Hosp, Coll Med, Seoul, South Korea
[16] Chelyabinsk Reg Clin Ctr Oncol & Nucl Med, Dept Gynaecol, Chelyabinsk, Russia
[17] Baskent Univ, Turkish Soc Gynecol Oncol TRSGO, Ankara, Turkey
[18] Merck & Co Inc, Oncol, Rahway, NJ USA
[19] Ist Nazl Tumori IRCCS Fdn G Pascale, Dept Urol & Gynecol, Naples, Italy
[20] Univ Virginia, Obstet & Gynecol, Sch Med, Charlottesville, VA USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.771
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
709O
引用
收藏
页码：S544 / S544
页数：1
相关论文
共 50 条
  • [21] Overall survival benefit of pembrolizumab plus chemoradiotherapy for patients with high-risk locally advanced cervical cancer
    Nierengarten, Mary Beth
    CANCER, 2025, 131 (02)
  • [22] A Phase 3 Study of Pembrolizumab plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer
    Cerrotta, Annamaria
    Macchia, Gabriella
    Christiaens, Melissa
    Lalondrelle, Susan
    Zhang, Xiang
    De Melo, Andreia Cristina
    Reginacova, Klaudia
    Helpman, Limor
    Ayhan, Ali
    Zagouri, Flora
    Woelber, Linn
    Hellman, Kristina
    Colombo, Nicoletta
    Romeo Marin, Margarita
    Berger, Regina
    Alejandra Lopez, Karla
    Castonguay, Vincent
    Takehara, Kazuhiro
    Chang, Ting-Chang
    Yamada, Karin
    Toker, Sarper
    Li, Kan
    Lorusso, Domenica
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S1124 - S1126
  • [23] ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
    Van Gorp, T.
    Cibula, D.
    Lv, W.
    Backes, F.
    Ortac, F.
    Hasegawa, K.
    Lindemann, K.
    Savarese, A.
    Laenen, A.
    Kim, Y. M.
    Bodnar, L.
    Barretina-Ginesta, M. -p.
    Gilbert, L.
    Pothuri, B.
    Chen, X.
    Flores, M. B.
    Levy, T.
    Colombo, N.
    Papadimitriou, C.
    Buchanan, T.
    Hanker, L. C.
    Eminowicz, G.
    Rob, L.
    Black, D.
    Lichfield, J.
    Lin, G.
    Orlowski, R.
    Keefe, S.
    Lortholary, A.
    Slomovitz, B.
    ANNALS OF ONCOLOGY, 2024, 35 (11) : 968 - 980
  • [24] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study
    Colombo, N.
    Dubot, C.
    Lorusso, D.
    Caceres, V.
    Hasegawa, K.
    Shapira-Frommer, R.
    Tewari, K. S.
    Salman, P.
    Hoyos, E.
    Yanez, E.
    Gumus, M.
    De Mendoza, M. Olivera Hurtado
    Samouelian, V.
    Castonguay, V.
    Arkhipov, A.
    Toker, S.
    Li, K.
    Keefe, S. M.
    Monk, B. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1307 - S1308
  • [25] ENGOT-EN11/GOG-3053/KEYNOTE-B21: PHASE 3 STUDY OF PEMBROLIZUMAB OR PLACEBO plus ADJUVANT CHEMOTHERAPY ± RADIOTHERAPY FOR HIGH-RISK ENDOMETRIAL CANCER
    Van Gorp, T.
    Mirza, M. R.
    Lortholary, A.
    Vergote, I. B.
    Cibula, D.
    Walther, A.
    Savarese, A.
    Barretina-Ginesta, M. P.
    Ortac, F. U.
    Papadimitriou, C.
    Bodnar, L.
    Lai, C. H.
    Hasegawa, K.
    Xie, X.
    Barber, E. L.
    Coleman, R.
    Lichfield, J.
    Grandhi, A.
    Slomovitz, B.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A79 - A80
  • [26] KEYNOTE-826: FINAL OVERALL SURVIVAL RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF PEMBROLIZUMAB plus CHEMOTHERAPY VS PLACEBO plus CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
    Monk, Bradley J.
    Colombo, Nicoletta
    Tewari, Krishnansu Sujata
    Dubot, Coraline
    Caceres, M. Valeria
    Hasegawa, Kosei
    Shapira-Frommer, Ronnie
    Salman, Pamela
    Yanez, Eduardo
    Gumus, Mahmut
    De Mendoza, Mivael Olivera Hurtado
    Samouelian, Vanessa
    Castonguay, Vincent
    Arkhipov, Alexander
    Tekin, Cumhur
    Li, Kan
    Keefe, Stephen Michael
    Lorusso, Domenica
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A420 - A420
  • [27] KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
    Monk, Bradley J.
    Colombo, Nicoletta
    Tewari, Krishnansu Sujata
    Dubot, Coraline
    Caceres, M. Valeria
    Hasegawa, Kosei
    Shapira-Frommer, Ronnie
    Salman, Pamela
    Yanez, Eduardo
    Gumus, Mahmut
    de Mendoza, Mivael Olivera Hurtado
    Samouelian, Vanessa
    Castonguay, Vincent
    Arkhipov, Alexander
    Tekin, Cumhur
    Li, Kan
    Keefe, Stephen Michael
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study
    Mayadev, Jyoti
    Nunes, Ana T.
    Li, Mary
    Marcovitz, Michelle
    Lanasa, Mark C.
    Monk, Bradley J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (07) : 1065 - 1070
  • [29] KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC
    Cortes, J.
    Cescon, D. W.
    Rugo, H. S.
    Im, S-A.
    Yusof, M. Md
    Gallardo, C.
    Lipatov, O.
    Barrios, C. H.
    Perez-Garcia, J.
    Iwata, H.
    Masuda, N.
    Otero, M. Torregroza
    Gokmen, E.
    Loi, S.
    Guo, Z.
    Zhou, X.
    Karantza, V.
    Pan, W.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1289 - S1290
  • [30] DURVALUMAB, IN COMBINATION WITH AND FOLLOWING CHEMORADIOTHERAPY, IN LOCALLY ADVANCED CERVICAL CANCER: RESULTS FROM THE PHASE 3 INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CALLA TRIAL
    Monk, Bradley
    Toita, Takafumi
    Wu, Xiaohua
    Carlos Limon, Juan
    Zhou, Qi
    Tarnawski, Rafal
    Mandai, Masaki
    Shapira-Frommer, Ronnie
    Mahantshetty, Umesh
    Estevez-Diz, Maria Del Pilar
    Ramirez Godinez, Francisco
    Varga, Szilvia
    Leiva Galvez, Manuel Humberto
    Lee, Jung-Yun
    Kreynina, Yulia
    Howells, Kathryn
    Wildsmith, Sophie
    Dry, Hannah
    Nunes, Ana
    Mayadev, Jyoti
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A2 - A3
12345